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Abstract
Background: Reactivation of hepatitis B or C virus can occur in patients undergoing chemotherapy.
Recommendations for selective or systematic hepatitis B virus testing prior chemotherapy for solid tumors differ.
The primary aim was to determine the seroprevalence of hepatitis B or C in a low endemic country. The second
objective was to assess the relevance of a questionnaire on hepatitis B/C risk factors to consider a selective
screening.
Methods: Patients were prospectively tested for hepatitis B/C markers. HBs antigen positive patients and isolated
anti-HBc positive patients with detectable viral load received antiviral preventive treatment. Patients or physicians
completed the questionnaire on infection risk factors.
Results: Among the 450 patients included, 388 were tested for all serological markers and had gastrointestinal
(63.7 %), lung (31.2 %) and skin (4.6 %) cancers. The prevalence of subjects exposed to hepatitis B virus was 8.5 %
(33/388). One patient tested positive for HBs antigen and received preventive treatment. Prevalence of subjects
exposed to hepatitis C was 1.3 % (5/388). The questionnaire sensitivity was 45.5 %, 100 % and 50 % for detecting
carriers of hepatitis B, C and one or the other, respectively.
Conclusions: Seroprevalence of hepatitis B was low. Selective screening with the questionnaire was insufficiently
sensitive. Systematic screening with serological tests prior to chemotherapy in patients with solid tumors is
therefore relevant.
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Background
Infection with hepatitis B virus (HBV) and hepatitis C
virus (HCV) is a major public health problem but many
patients are not aware of their status. In France, this
figure is approximately 50 % [1]. Immunosuppression in-
duced by cancer treatment increases the risk of HBV re-
activation (HBVR)[2, 3]. HCV reactivation (HCVR) is
uncommon and its morbidity and mortality is less sig-
nificant [4, 5].
HBVR may be asymptomatic but it can cause ful-
minant hepatitis and death. Additionally, HBVR may
require the treatment of cancer to be modified in-
cluding delaying or stopping chemotherapy [6]. This
risk is present during treatment and also after stop-
ping during the immunological rebound. The risk per-
sists for at least 6 months after cessation [7].
The risk of HBVR depends on three main elements:
host, cancer treatment and serological status [7, 8]. Ef-
fective preventive approach of HBVR is possible through
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antiviral treatment. While a HCV antiviral treatment is
rarely compatible with chemotherapy, new findings will
unquestionably result in new anti-HCV drugs.
Serological testing is the key to the prevention of
HBVR. However, it can also be problematic since inter-
national recommendations differ. Hepatologists and in-
fectious disease specialists (EASL, AASLD, APASL,
CDC, NIH) recommend routine screening HBV of all
candidates for immunosuppressive therapy [9–13].
These recommendations are implemented mostly by he-
matologists, given the frequency of HBVR associated to
hematological malignancies [14, 15]. Guidelines of clin-
ical oncology organizations (ASCO, NCCN, ESMO) sug-
gest a selective screening in case of risk factors of
hepatitis B or in patients with a strong immunosuppres-
sion (such as anti-CD20 based treatment, stem cell
transplantation or lymphoma treatment) [16–18].
These differences result in inadequate screening by
oncologists [14, 15] and cases of fatality. Screening be-
fore cytotoxic chemotherapy for solid tumors in coun-
tries with low prevalence of HBV is questionable and
selective screening of patients at risk HBV can be
assessed.
The primary endpoint of this study was to evaluate the
seroprevalence of HBV and HCV in patients receiving
cytotoxic chemotherapy for solid tumors. Secondary
endpoints were (i) to assess the relevance of screening
questions to detect risk factors of HBV and HCV and (ii)
to analyze the patients with superior risk of viral
reactivation.
We chose to examine these 2 objectives for HBV and
HCV although HCV seems less relevant clinically.
Methods
In a single-center cross-sectional study, all consecutive
patients receiving chemotherapy for solid tumors in the
Ambulatory Medicine Unit of the Reims University
Hospital (France) were prospectively assessed between
May 14, 2012 and July 31, 2013. Local ethics council
(Reims Institutional Review Board – approval # CCTIRS
13.027 from the French Comité Consultatif sur le Traite-
ment de l’Information en matière de Recherche dans le
Domaine de la Santé)) according to the Declaration of
Helsinki approved the study.
Investigation scheme
Patients were informed on the objectives and methods
of the study and patients provided an oral consent,
accordingly with the CCTIRS approval If the patient
agreed to participate, HBV and HCV serology were
ordered and a screening questionnaire (Additional
file 1) was submitted (self-administered or straight
questionnaire, according to the patient’s level of the
understanding/knowledge/intelligence) on the risk
factors for exposure to HBV and/or HCV. The ser-
ology reviewed was: HBsAg, anti-HBc, anti-HBs and
anti-HCV. Questions are listed in Table 1.
Questionnaires were considered evaluable if (i) all re-
sponses were answered, without regard to the answer
being positive or negative or (ii) incomplete with at least
one positive answer to one question. Countries at risk
were South East Asia, Middle East, Africa or South
America. Patients’ management according to their sero-
logical status is shown in Fig. 1. HBsAg (+) patients
(regardless of the viral load) and isolated anti-HBc (+)
patients (with detectable viral DNA load) were consid-
ered at risk for HBVR.
Collected data
The data collected in this study were: (i) clinical data
[sex, age, tumor location, date of diagnosis, type of anti-
cancer treatment (cytotoxic chemotherapy, targeted
biotherapy) and therapeutic strategy (curative or pallia-
tive)], (ii) the results and dates for HBV and HCV ser-
ology, (iii) data of the screening questionnaire for risk
factors and, (iv) specific clinical data of superior risk
patients for reactivation (positive HBsAg, isolated anti-
HBc, positive HCV or receiving anthracycline).
Data management
All data were recorded on a standardized collection
sheet specific to this study and included in a specific
database (Epi Info® software, v. 3.5.1, Centers for Disease
Control and Prevention - CDC).
Table 1 Positive responses to risk factors questions
Risk factor questions n (%)
Major surgery/bleeding prior 1992 57 (15.1)
Acupuncture, tattoo or piercing without disposable devices a 55 (14.6)
Icterus 28 (7.4)
Liver disease other than cancer 23(6.1)
Transfusion prior 1992 b 20 (5.3)
Relatives with viral hepatitis 18 (4.8)
Grand prematurity or serious health problem at birth 13(3.5)
Birth or medical care in countries at risk 10(2.7)
Transplantation prior 1992a 6 (1.6)




One or more risk factor 165 (44.0)
a one missing data b two missing data
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Statistical analysis plan
Quantitative variables were described as median and
range and qualitative data as number and percentage [n
(%)]. Comparing patients with and without serological
tests were performed using univariate analyses (t test,
Wilcoxon test, KHI2 test, or Fisher exact test, as deemed
appropriate). Sensitivity (Se), specificity (Sp), positive
predictive value (PPV), negative predictive value (NPV)
were calculated for the screening of subjects exposed to
HBV, subjects exposed to HCV and subjects exposed to
one or the other (each question of the questionnaire and
global questionnaire). All statistical analyses were per-
formed using SAS® version 9.3 (SAS Institute Inc).
Results
HBV/HCV seroprevalence
Four hundred and fifty patients with solid tumors re-
ceived anticancer treatment between May 14, 2012 and
July 31, 2013 at the Ambulatory Medicine Unit of Reims
University Hospital (France).
All HBV and HCV markers were tested in 388 of the
450 patients (86.2 %) (Fig. 2).
The characteristics of the 388 patients are presented in
Table 2. More than half (63.7 %) had a gastrointestinal
cancer. Among gastrointestinal cancers, half of were colo-
rectal cancers. The most prescribed anticancer treatment
was a cytotoxic doublet without biotherapy (49.7 %, n =
193). Most of the patients (79.9 %) were in a palliative
treatment strategy.
Missing data was due to (i) the patients’ refusal, or (ii)
to deliberate or not non-prescription.
The 62 patients without HBV and HCV serology did
not differ in age (p = 0.59), sex (p = 0.86), type of chemo-
therapy (mono or poly-chemotherapy) (p = 0.50) and
therapeutic strategy (p = 0.10). Patients with gastrointes-
tinal cancer were more likely to be tested than other pa-
tients (p <0.0001). Patients not tested had a significantly
older diagnosis than the tested patients (p = 0.03).
HBV and HCV assays results are shown in Table 3.
The prevalence of present or past HBV was 8.5 % (n =
Fig. 1 Patients’ management according to their serological status
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33). Only one patient was tested positive for HBsAg.
The seroprevalence of HCV was 1.3 % (n = 5).
Risk factors for HBV/HCV carriage
In 388 tested patients, the questionnaire was evaluable
in 377 patients (83.7 % of the included cohort; n = 450)
(Fig. 2).
Among the 11 patients without evaluable question-
naire, 9 were seronegative and 2 were vaccinated against
VHB.
Positive responses for risk factors from the question-
naire are shown in Table 1. Forty-four percent of pa-
tients (165/377) had at least one risk factor.
Countries cited by the patients and considered to
be at risk were the Sub-Saharan Africa (Senegal,
Mauritania, Madagascar, and Guinea), the South East
Asia (Indochina, Vietnam twice) and the Middle East
(Iraq). This information was not available for 2 pa-
tients although they indicated a positive response to
this question.
Relevance of screening questionnaire
Se, Sp, PPV and NPV of each risk factor questions and
combined (one or more risk factors) are shown in
Table 4.
The most sensitive item was history of liver disease
(22.2 % [8.6-35.8]). The two most specific items were
HIV seropositivity (100 %) and intravenous drug use
(99.7 % [99.1-100.0], limited to thèse two patients).
Patients with superior risk of reactivation
The only patient tested HBsAg positive was treated with
pemetrexed for advanced non-small cell lung carcinoma
diagnosed 10 months before performing serology. This
patient was unaware of his status. He did not present
with any risk factor for HBV carriage. DNA viral load
was undetectable but, in accordance with recommenda-
tions, the patient was treated with entecavir (0.5 mg per
day). Regular monitoring was conducted with a hepatol-
ogist. HCV serology was negative.
A therapeutic break was proposed due to prolonged
tumoral stability. Entecavir was stopped 6 months after
cessation of chemotherapy while monitoring DNA viral
load continued for 3 months. No viral reactivation was
demonstrated at 20 months of follow-up after initiation
of the treatment.
Eight patients had isolated anti-HBc. The DNA viral
load achieved in five patients was negative; the other 3
patients declined rapidly and expired from their cancer.
One of these 8 patients had a risk factor for HBV car-
riage (born in Guinea); assessment of the DNA viral load
could not be performed in this patient. No patient was
seropositive for HCV. In accordance with the guidelines,
patients having a negative DNA viral load did not receive
antiviral treatment.
Five patients were anti-HCV (+). This status was
known by two of the five patients and were followed un-
treated. The three who were unaware of their status had
identified a risk factor in the questionnaire (tattoo, albu-
min prior to 1988 and liver disease history).
Only 4 patients received anthracylines. Three patients
received epirubicin 50 mg/m2 combined with oxaliplatin
and capecitabine (EOX regimen) for metastatic gastric
cancer. Two were negative for HBV, one being properly
vaccinated, and were seronegative for HCV. No indica-
tion of risk factors for HCV or HBV carriage were noted
Fig. 2 Primary and secondary endpoint populations
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for these patients. A patient received doxorubicin
50 mg/m2 (day 1 and day 22) combined with streptozo-
tocin for metastatic pancreatic neuroendocrine tumor
(Zollinger Ellison Syndrome). The patient refused sero-
logical assays and participation in the questionnaire. No
significant cytolysis was seen retrospectively during the
16 months following the initiation of polychemotherapy.
Discussion
HBV/HCV seroprevalence
This study presents a prospective assessment for the
seroprevalence of HBV and HCV in patients receiving
cytotoxic chemotherapy for solid tumors in a country
with low endemicity of HBV and HCV. Other studies
examining these factors exist but the countries assessed
were high endemic [3, 6, 8] or intermediate endemic
[19–21] prevalence.
In our population, the prevalence of chronic HBV
[HBsAg (+)] was lower than that of the general popula-
tion in France (0.3 % vs. 0.65 %) [1] but higher (0.3 % vs.
0.11 %) than the French hospital prevalence [22]. The
target population for selective screening consists of sub-
jects exposed to HBV. Seroprevalence in these patients
(8.5 %) was identical to the French general population
favoring the extrapolation of these results [1].
The seroprevalence of HCV (1.3 %) was higher
when compared to both the French general (0.84 %)
[1] and hospital populations (0.33 %) [22]. One con-
tributing factor for this observation may have been
due to an increased risk of receiving a transfusion or
other procedural contamination prior to 1992 due to
the age of these patients.
Rationale for selective screening
Systematic HBV screening in patients with solid tumors
may not be as cost-effective as chemotherapy when the
HBVR and the prevalence of HBV are low [23]. The esti-
mated cost of care and cost-effectiveness ratio is consid-
ered relevant. Cost effectiveness depends on the care
system of the country and therefore studies of cost -ef-
fectiveness are difficult to extrapolate from one country
to another.
The HBVR risk depends on three components: the type
of solid tumor, the treatment and the serological status.
This risk was more prevalent in breast cancer (estimated
up to 41 %) [6, 7] and hepatocellular carcinoma patients
(36 %) [24]. In other solid tumor, HBVR risk was approxi-
mately 16 % in prospective studies [3, 7]. Our population
did not include patients with breast cancer and included
Table 2 Characteristics of the patients, tumors and treatment





Median (range) 64 [24–89]
Tumor localization
Gastrointestinal 247 (63.7)
Colon rectum 124 (50.2)
Pancreas 43 (17.4)








Other (Adrenocortical carcinoma) 1 (0.3)
Unknown 1 (0.3)
Treatment regimens












Table 3 Hepatitis B virus and hepatitis C virus serological status
Total (n = 388) [n (%)]
HBV exposed 33 (8.5)
Chronic HBV infection a 1 (0.3)
Past HBV infection 32 (8.3)
Isolated anti-HBc b 8 (2.0)
Anti-HBc (+) and 24 (6.2)
anti-HBs (+) c
HBV vaccine d 56 (14.4)
HBV negative e 299 (77.0)
HCV positive 5 (1.3)
HCV negative 383 (98.7)
HBV: hepatitis B virus; HCV: hepatitis C virus
a HBsAg (+), anti-HBc (+), anti-HBs (−) b HBsAg (−), anti-HBc (+), anti-HBs (−) c
HBsAg (−), anti-HBc (+), anti-HBs (+) d HBsAg (−), anti-HBc (−), anti-HBs (+)
[anti-HBs ≥ 10 IU/mL] e HBsAg (−), anti-HBc (−), anti-HBs (−)
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Table 4 Sensibility, specificity, positive predictive value and negative predictive value of risk factors questions for hepatitis B virus positivity, hepatitis C virus positivity and
hepatitis B or hepatitis C positivity

























Major surgery/bleeding prior 1992 15.2 84.9 8.8 91.3 0.0 84.6 0.0 98.4 13.9 84.7 8.8 90.3
[2.9-27.4] [81.1-88.7] [1.4-16.1] [88.2-94.3] [81.0-88.3] [97.1-99.8] [2.6-25.2] [80.9-88.5] [1.4-16.1] [87.0-93.5]
Acupuncture, tattoo or piercing
without disposable devices
12.5 85.2 7.3 91.3 40.0 85.7 3.6 99.1 14.3 85.3 9.1 90.6
[1.0-24.0] [81.4-88.9] [0.4-14.1] [88.2-94.4] [0.0-82.9] [82.1-89.2] [0.0-8.6] [98.0-100] [2.7-25.9] [81.5-89.1] [1.5-16.7] [87.4-93.8]
Icterus 12.1 93.0 14.3 91.7 40.0 93.0 7.1 99.1 13.9 93.2 17.9 91.1
[1.0-23.3] [90.3-95.7] [1.3-27.2] [88.8 -94.6] [0.0-82.9] [90.4-95.6] [0.0-16.7] [98.2-100.0] [2.6-25.2] [90.6-95.9] [3.7-32.0] [88.1-94.1]
Liver disease other than cancer 18.2 95.1 26.1 92.7 60.0 94.6 13.0 94.9 22.2 95.6 34.8 92.1
[5.0-31.3] [92.8-97.3] [8.1-44.0] [89.6 -95.1] [17.1-100.0] [92.3-96.9] [0.0-26.8] [92.6-97.1] [8.6-35.8] [93.4-97.8] [15.3-54.2] [89.2-94.9]
Transfusion prior 1992 3.0 94.4 5.0 91.0 0.0 94.6 0.0 98.6 2.8 94.4 5.0 90.1
[0.0-8.9] [92.0-96.9] [0.0-14.6] [88.0-94.0] [92.3-96.9] [97.4-99.8] [0.0-8.1] [91.9-96.8] [4.6-14.6] [87.0-93.2]
Relatives with viral hepatitis 6.1 95.3 11.1 91.4 0.0 95.1 0.0 98.6 5.6 95.3 11.1 90.5
[0.0-14.2] [93.1-97.6] [0.0-25.6] [88.5 -94.3] [93.0-97.3] [97.4-99.8] [0.0-13.0] [93.0-97.5] [0.0-25.6] [87.5-93.5]
Grand prematurity or serious
health problem at birth
0.0 96.2 0.0 90.9 0.0 96.5 0.0 98.6 0.0 96.2 0.0 97.6
[94.2-98.2] [88.0-93.9] [94.6-98.4] [97.4-99.8] [94.1-98.2] [95.9-99.2]
Birth or medical care in countries
at risk
3.0 97.4 10 91.3 0.0 97.3 0.0 98.9 2.8 97.4 10 90.4
[0.0-8.9] [95.7-99.1] [0.0-28.6] [88.4-94.2] [95.7-99.0] [97.4-99.8] [0.0-8.1] [95.6-99.1] [0.0-28.6] [87.4-93.5]
Transplantation prior 1992 0.0 98.3 0.0 91.1 0.0 98.4 0.0 98.6 0.0 98.2 0.0 90.2
[96.9-99.6] [88.2-94.0] [97.1-99.7] [97.5-99.8] [96.8-99.6] [87.2-93.3]
Blood derived product prior 1988 3.0 98.8 20.0 91.4 20 98.9 20 98.9 2.9 98.8 2 90.5
[0.0-8.9] [97.7-100.0] [0.0-55.1] [88.5-94.2] [0.0-55.1] [97.9-100] [0.0-55.1] [97.9-100.0] [0.0-8.4] [97.7-100] [0.0-55.1] [87.6-93.5]
Hemodialysis 0.0 99.4 0.0 91.2 0.0 99.5 0.0 98.7 0.0 99.4 0.0 90.4
[98.6-100.0] [88.3 -94.1] [98.7-100.0] [97.5-99.8] [98.6-100.0] [87.4-93.4]
Intravenous drug 3.0 100.0 100.0 91.5 0.0 99.7 0.0 98.7 2.8 100.0 100.0 90.7
[0.0-8.9] [88.7 -94.3] [99.2-100.0] [97.5-99.8] [0.0-8.1] [87.7-93.6]
Human Immunodeficiency Virus + 0.0 99.7 0.0 91.2 0.0 99.7 0.0 98.7 0.0 99.7 0.0 90.4
[97.1-100.0] [88.3-94.1] [99.2-100.0] [97.5-99.8] [99.1-100.0] [87.4-93.4]
One or more risk factor 45.5 56.4 9.1 91.5 100.0 56.9 3.0 100.0 50.0 56.8 10.9 91.5
[28.5-62.4] [51.2-61.6] [4.7-13.5] [87.8-95.3] [51.8-61.9] [0.4-5.6] [33.7-66.3] [51.5-62.0] [6.2-15.7] [87.7-95.2]











only one patient with liver cancer; making the RVHB risk
low.
The highest rates of HBVR in patients undergoing
chemotherapy for solid tumors occurred with
anthracycline-based regimen [6, 7]. This type of regimen
is rarely used outside of breast cancer (FEC/AC); as
reflected in our study with only 4 patients who received
an anthracycline.
According to the serological status, 9 patients were
considered at risk of reactivation (2 %), which shows a
possible benefit of screening. But the only patient treated
was HBsAg (+). Among 388 screened patients only one
was treated, which probably decreases the relative cost-
effectiveness of a routine screening. Moreover, the only
solid tumor cost-efficiency study suggested a screening
with HBsAg alone [23], since the HBsAg (+) patients are
most at risk of HBVR.
The screening questionnaire shows the need for oncol-
ogists to be educated on risk factors for carriage of
HBV/HCV since only 33 % identified the place of birth
in endemic areas as a risk factor (while being the main
risk [15, 25]).
We found that our population was ideal for a selective
screening. To our knowledge, and from the time of this
publication, there have been no published evaluations
for the selective screening process considering sensitiv-
ity, specificity, and predictive value in a low endemic
country for viral hepatitis.
Relevance of targeted screening on HBV/HCV risk factors
Selective screening is performed in two steps: a pre-
screening (questionnaire), followed by the serological
test. A quality pre-screening test will focus on sensitivity
while a quality serological test will focus on specificity.
In the present study, the sensitivity for HBV was
45.5 %, leaving out more than half of seropositive HBV
patients. Additionally, the only patient HBsAg (+) would
not have been identified and treated using a selective
strategy since he had no risk factor on the questionnaire.
The overall sensitivity (exposed to HBV or HCV) was
50 %, therefore insufficient. Sensitivity was 100 % for
HCV but, as stated previously, HCV infection is not the
main concern. The specificity of the questionnaire was
also insufficient (56 %, approximately).
The probability of being seropositive for HBV, HCV
and one or the other in case of positive questionnaire
was very low since the overall PPV did not exceed 11 %.
Recalling the differences in clinical outcome of RHCV,
the screening recommendations for HBV and HCV can-
not be the same.
Few studies have assessed the relevance of targeted
screening on HBV / HCV risk factors [26–28]. One
study with pregnant women in the United States was de-
signed to test a questionnaire recommended by the
ACIP (Advisory Committee on Immunization Practices).
This questionnaire was used for 692 parturient women
among whom 8.5 % were HBV positive. The sensitivity
was less than 60 % for screening carriers of HBV[28] .
These findings led to the current policy of universal pre-
natal screening.
Limitations
This study is missing data
It was noted that serologic test were not ordered due to
either (i) deliberate from relevance deemed insufficient
by the oncologist because of the entry into advanced pal-
liative/terminal phase or (ii) unintentional due to lack of
awareness of oncologists despite the study implementa-
tion. Without a doubt, there is an underestimation for
the risk of RHBV by oncologists [15] although it is pos-
sible to conclude that digestive oncologists may be more
informed on this since patients with gastrointestinal tu-
mors were more likely to be tested in our study.
This questionnaire is lacking in sensitivity. First, the
main mode (one third of cases) of transmission of
HBV,[1] is sex. Except for HIV seropositivity and noting
relatives infected with viral hepatitis, sexually transmit-
ted infections were intentionally excluded from the ques-
tionnaire due to the subjectivity of the concept of unsafe
sex and the lack of reliability of predictable responses.
Secondly, lack of sensitivity of our survey for HBV could
be expected; actually, in one third of cases the mode of
transmission of hepatitis B is not found [1]. However, it
had to be proven; we can conclude that, in our popula-
tion, if a screening must be done, it has to be systematic,
especially since serologic test is sensitive, specific and
inexpensive.
The CDC (Centers for Disease Control and Preven-
tion) developed a on-line questionnaire specifically for
these risk factors which was completed by patients [29].
The estimated time to complete this questionnaire was
5 minutes [29]. This questionnaire is being used in an
ongoing prospective study at the MD Anderson Cancer
Center (USA), which is to include 3,400 patients prior to
chemotherapy and to compare both strategies in terms
of sensitivity, specificity and cost-effectiveness [30]. This
questionnaire could have a different sensitivity. The reli-
ability of patients’ anamnestic data and their lack of edu-
cation for risk of contamination (i.e. infected patients
who do not recognize or report on risk factors) remain
to be an issue.
Conclusions
In conclusion, two main observations can be drawn from
this study: (i) a very low prevalence of chronic HBV in our
population with only one patient who received antiviral
treatment and (ii) a lack of sensitivity of the screening
questionnaire on viral hepatitis risk factors. These results
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support the relevance of routine screening with serological
tests prior chemotherapy in patients with solid tumors.
Another type of selective screening based on risk of
viral reactivation (relying on the type of chemotherapy
and cancer) is possible; more robust data are needed to
determine the incidence and predictive factors for
HBVR. Development of a register to track viral reactiva-
tion cases would be useful.
Expecting consensual recommendations that will
harmonize and simplify practices, oncologists’ education
and collaboration with hepatologists must be initiated or
continued.
Additional file
Additional file 1: QUESTIONNAIRE. (PDF 54.5 kb)
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